NADMED method has been used to detect NAD levels in muscle myopathy study conducted by several renowned parties namely NIH, National Institute of Nursing Research, University of Rochester Medical Center, National Institute of Neurological Disorders and Stroke, Biogen Inc., and NADMED Ltd.

The study discloses the systemic NAD+ deficiency that reveals a potential therapeutic target for RYR1-related myopathies. The study paper will be published for the 28th International Annual Congress of the World Muscle Society that will take place 3rd – 7th October 2023, in Charleston, South Carolina, United States.